MedTrace Logo

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122512 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-02-10

No results posted yet for this study

Summary

This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended safety data for high-risk men. Secondarily, the study will assess the feasibility of conducting the trial and evaluate the preliminary effectiveness of TDF 300 mg as an HIV prevention method when taken once a day.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir Disoproxil Fumarate

Sponsors & Collaborators

  • FHI 360

    lead OTHER

Principal Investigators

  • Irving Hoffman, PA, MPH · UNC Center for Infectious Diseases

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122512 on ClinicalTrials.gov